FDA panel backs previously rejected heaviness pill
SILVER SPRING, Md. — A panel of advisers to the Food and Drug Administration overwhelmingly backed endorsement in favor of a highly anticipated anti-obesity pill from Vivus Inc., a drug which the FDA previously rejected due to safety concerns.The FDA panel of outside physicians voted 20-2 here good deed of the authority loss drug Qnexa, setting the stage used for a likely comeback used for a drug to facilitate has been plagued by plane belongings since it was to start with submitted to the agency here 2010.A majority of panelists ultimately backed the drug due to its impressive heaviness loss results, with on the whole patients exposure practically 10 percent heaviness loss. But the knot stressed the meaning of confirming the drugs safety, particularly its special effects the focal point, by tracking patients indoors a big, follow-up study.